coagulants their place in the long term management of coronary artery disease is still disputed" . . . B.M.J, leader February 1970 (2) .
It is more of a reflection on the limitations of the tests used to control anticoagulants. For example, after the publication of the most recent M.R.C. report on the use of anticoagulants after cardiac infarction (10), it became apparent that three years work in eleven centres involving nearly 1500 patients was invalidated because the level of anticoagulant control ?although that originally advocated by the manufacturers of the thromboplastin used?had since been shown to result in homeopathic dosages well below the therapeutic range (").
The function of any test used for anticoagulant control is to ensure that enough of the drug is given to prevent thrombotic episodes, yet not enough to cause haemorrhagic complications. In practice no one has determined just how much is necessary to prevent thrombosis, and the usual procedure is to give the maximum dose compatible with safety (1). The test must therefore be able to predict bleeding.
When blood escapes from a damaged vessel clotting is a relatively simple matter (Fig. 1) ACTIVATED PARTIAL THROMBOPLASTIN TIME The whole blood clotting time is too long and too variable to be used to control anticoagulants. The duration and variation are due to two steps which are both time consuming and unpredictably so (Fig. 4) . These are the activation of Factor XII, and the release of phospholipid from platelets. The 
